



## Altimune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

May 2, 2024 at 7:30 AM EDT

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.

Altimune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimune's Investor Relations website at <https://ir.altimmune.com/investors>.

Participants who would like to join the call may register [here](#) to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

### About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

### Company Contact:

Richard Eisenstadt  
Chief Financial Officer  
Phone: 240-654-1450  
[reisenstadt@altimmune.com](mailto:reisenstadt@altimmune.com)

### Investor Contact:

Lee Roth  
Burns McClellan  
Phone: 646-382-3403  
[lroth@burnsmc.com](mailto:lroth@burnsmc.com)  
Julia Weilman  
Burns McClellan  
Phone: 646-732-4443  
[jweilman@burnsmc.com](mailto:jweilman@burnsmc.com)

### Media Contact:

Danielle Cantey  
Inizio Evoke Comms  
Phone: 619-826-4657  
[Danielle.cantey@inizioevoke.com](mailto:Danielle.cantey@inizioevoke.com)



altimmune

Source: Altimune, Inc